Sustained Release Ocular Drug Delivery: Mapping the Future Potential

Roots Analysis has announced the addition of Ocular Drug Delivery Systems Market report to their offering. The report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.

Raghav Goyal, the lead analyst, said, “In the recent past, the market has witnessed an uphill trend with the launch of Ozurdex and Iluvien for the treatment of Diabetic Macular Edema (DME). In addition, several new systems have entered into preclinical and clinical stages of development. The commercial uptake is still limited with the presence of only three sustained release systems in the market. This presents a significant opportunity for current players; we certainly expect it to witness strong growth in near future”.

In fact, one of the key objectives of this report is to understand the future state of the industry. The report forecasts that the overall market is likely to be more than USD 6 billion in the coming decade; significant upside could be achieved by the successful approval of implants to deliver biologics. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry such as Neurotech Pharmaceuticals, Mati Therapeutics, On Demand Therapeutics and Euclid Systems.

Goyal further stated, “Even though there are several challenges to overcome, the sustained release ocular drug delivery systems market is inundated with huge opportunities. DME and Uveitis will provide the much needed boost in the short-term. In the mid-long term, growth will be driven by launch of sustained release systems for glaucoma and AMD. More than 15 sustained release formulations are under evaluation for the treatment of glaucoma; majority of these are undergoing preclinical studies.”

Who will benefit from this report?

The research is targeted towards big and small pharma companies working in the field of ocular drug delivery systems. In particular, you could benefit if you are an:

• Investor
• CXO level decision maker
• R&D manager
• Business Intelligence / Scientific analyst
• Finance manager
• Strategy head

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/96/request-sample.html 

For additional details, please email at sales@rootsanalysis.com

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for over a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.